RHYTHM PHARMACEUTICALS INC

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

RYTM$113.95+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)



· · Three months ended March 31,
	2025		2024
Revenues:
Product revenue, net		$37,718		$25,967
License revenue		(5,014)		—
Total revenues		32,704		25,967
Costs and expenses:
Cost of sales		3,648		2,807
Research and development		36,973		128,665
Selling, general, and administrative		39,087		34,382
Total costs and expenses		79,708		165,854
Loss from operations		(47,004)		(139,887)
Other income (expense):
Other income (expense), net		(644)		524
Interest expense		(5,409)		(4,755)
Interest income		3,639		3,046
Total other (expense), net		(2,414)		(1,185)
Loss before income taxes		(49,418)		(141,072)
Provision for income taxes		80		300
Net loss		$(49,498)		$(141,372)
Accrued dividends on convertible preferred stock		(1,322)		—
Net loss attributable to common stockholders		$(50,820)		$(141,372)
Net loss per share attributable to common stockholders, basic and diluted		$(0.81)		$(2.35)

Weighted-average common shares outstanding, basic and diluted		63,059,165		60,143,558

Other comprehensive loss:
Net loss attributable to common stockholders		$(50,820)		$(141,372)
Foreign currency translation adjustment		(2)		(71)
Unrealized (loss), net on marketable securities		(10)		(244)
Comprehensive loss		$(50,832)		$(141,687)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.